ArticleTransplant infectious disease : an official journal of the Transplantation Society
Optimizing Pneumocystis jirovecii Prophylaxis in Immunocompromised Patients: Defining the Clinical Role of Atovaquone.
Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPneumocystis jirovecii pneumonia (PJP) is associated with poor outcomes in immunocompromised patients. Cotrimoxazole is the first-line prophylactic agent, with atovaquone an alternative. At our center, atovaquone use considerably increased after 2020. The aims of this retrospective cohort study were to understand the usage of atovaquone over time and explore the reasons for this increase.
methodsPatients receiving atovaquone for PJP prophylaxis from 2015 to 2022 were included. Clinical data were extracted to characterize atovaquone prescribing patterns and cotrimoxazole contraindications, with comparisons made between patients before 2020 and those afterward.
resultsHere, 149 patients were included, 24 (16%) before 2020 and 125 (84%) after 2020. The cohort comprised solid organ transplant recipients (49%), patients with hematologic conditions (35%), and human immunodeficiency virus (5%). Reasons for not prescribing cotrimoxazole included cytopenias (37%), renal impairment (15%), and drug interactions (12%). Median duration was significantly longer after 2020 (6.0 vs. 2.3 months, p = 0.047). Before 2020, most patients (71%) had underlying hematologic disease, but after 2020, solid organ transplant recipients accounted for 60%. Renal impairment appeared as a contraindication to cotrimoxazole only post-2020. After atovaquone, 67 patients transitioned to an alternative, most commonly cotrimoxazole (56/67, 84%). There were no breakthrough PJP cases. DISCUSSION: Atovaquone is an alternative PJP prophylaxis agent, used predominantly when cotrimoxazole is not tolerated. Increased usage was related to broader indications, uptake in new patient groups, difficulty tolerating or accessing alternatives, and longer durations. While atovaquone appears safe and effective, regular review of patients receiving it could facilitate reassessment of the initial indication, aiming to reinstate cotrimoxazole whenever appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.